目的：评价视网膜静脉阻塞(RVO)继发黄斑水肿抗血管内皮生长因子(VEGF)治疗前后黄斑区视网膜血管密度的变化。

方法：回顾性病例对照研究。选取2018-04/06临床确诊为RVO继发黄斑水肿患者23例，给予玻璃体腔注射0.5mg/0.05mL康柏西普。对比治疗前后BCVA以及行OCTA检查，软件自动识别及测量治疗前后CMT和浅层视网膜毛细血管网血管长度密度和灌注密度的变化。

结果：随访时间为1mo，治疗后BCVA较治疗前提高(P<0.05)，CMT较治疗前降低(P<0.05)，治疗后浅层视网膜毛细血管网中位于中心凹、旁中心凹及总区域的血管长度密度和灌注密度与治疗前均无差异(P>0.05)。

结论：单次抗VEGF治疗RVO继发黄斑水肿在短期内BCVA和CMT明显好转，并且未加重黄斑缺血。

METHODS: A retrospective case control series, 23 cases with RVO secondary macular edema were included from April 2018 to July 2018. They were treated with 0.5mg/0.05mL intravitreal injection of conbercept. To compare the best corrected visual acuity(BCVA)before and after treatment. Optical coherence tomography angiography(OCTA)images was obtained, central macular thickness(CMT)and vessel length density and perfusion density in the superficial retinal capillary plexus were measured before and after intravitreal injection.

RESULTS: The mean interval between baseline and follow up was 1mo. The improvement of BCVA, the decreased value of average central macular thickness after treatment were better than before(P<0.05). The vessel length density and perfusion density at the central, inner and full region in the superficial retinal capillary plexus was not significantly different after intravitreal injection(P>0.05).

CONCLUSION: The average BCVA and the mean CMT of patients with RVO secondary macular edema after treatment was significantly better, and it is not progressive macular ischemia in the short-term after a single intravitreal injection of an anti-VEGF agent.